Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2018-04-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
平安证券股份有限公司关于普莱柯生物工程股份有限公司对部分暂时闲置募集资金和自有资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from Ping An Securities regarding the cash management of temporarily idle raised funds and company-owned funds by Pulike Bioengineering Co., Ltd. It references regulatory requirements and approvals related to the use of raised funds, details the amount and purpose of the raised funds, and describes the procedures and approvals for cash management activities. The document is a formal opinion or verification report by the sponsor institution rather than a financial report or announcement of financial results. It does not contain financial statements or earnings data, nor is it a notice of voting results or a proxy statement. It is not a report publication announcement since it contains substantive content and is not merely announcing the availability of a report. The document fits best into the category of Regulatory Filings (RNS) as it is a compliance-related verification opinion regarding the use of funds and cash management, which does not fit other more specific categories.
2018-04-27 Chinese
第三届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding multiple agenda items including approval of the 2017 annual report, 2017 financial statements, 2018 financial budget, profit distribution plan, internal control report, and the 2018 first quarter report. It includes voting results and references to detailed reports available on the stock exchange website. The document itself does not contain the full annual report or financial statements but rather the resolutions approving these reports and related matters. The document length is short (2050 characters) and it mainly announces decisions and approvals rather than presenting the full reports. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement of supervisory board resolutions and approvals, not the full annual report or interim report itself.
2018-04-27 Chinese
2018年第二次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality and procedural compliance of a company's 2018 second extraordinary general meeting of shareholders. It details the convening, attendance, voting procedures, and legal compliance of the shareholders' meeting. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of voting results but a legal opinion on the meeting's legality. Therefore, it fits best under the category of Regulatory Filings (RNS), as it is a legal compliance document related to a shareholders' meeting but not a direct report or announcement type defined elsewhere.
2018-04-27 Chinese
2017年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2017 by 普莱柯生物工程股份有限公司. It discusses the company's internal control evaluation, including financial and non-financial control defects, audit opinions, and corrective actions. The content is focused on internal control effectiveness and compliance with regulatory internal control standards. It is not a full annual report (10-K), nor an audit report in the traditional sense, but rather a specialized internal control evaluation report. Given the nature of the document, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations. The document length (5616 characters) and detailed content support this classification rather than a brief announcement or regulatory filing. FY 2017
2018-04-27 Chinese
北京德恒律师事务所关于普莱柯生物工程股份有限公司回购注销部分限制性股票事宜的法律意见
Regulatory Filings
2018-04-27 Chinese
2017年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2017 年年度报告摘要" which translates to "2017 Annual Report Summary". It contains detailed financial data including total assets, revenue, net profit, quarterly financial data, shareholder information, accounting policy changes, and company business overview. The presence of comprehensive financial statements and management discussion indicates this is a full annual report or a summary thereof. The document length is 6528 characters, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2017
2018-04-27 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.